← Leaderboards
Michelle H Larsen
University Of California At Davis
$5,472,600
Attributed
$9,873,808
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $846.3K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,873,808 · 9
By mechanism
R01$9,702,965 · 2
P51$122,583 · 3
R13$48,260 · 4
Top collaborators
- Kristina Abel7 shared
- Glenn J Fennelly7 shared
- Max O'Donnell5 shared
- W. Ray Waters2 shared
- Kogieleum Naidoo1 shared
- Threnesan Naidoo1 shared
- Adrie Jc Steyn1 shared
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisMycobacterium TuberculosisTransmission ProcessPreventInfectionDoseResponseCollaborationsMycobacterialIncidenceResearch PersonnelAttenuatedVaccinationVaccinesSafetyLifeResourcesMetabolicRegimenMacacaCountryPredispositionGlobal HealthInnovation
Grant awards (25)
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes$846,347
R01 · FY2025 · AI · contact PI
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes$723,278
R01 · FY2024 · AI · contact PI
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes$726,583
R01 · FY2023 · AI · contact PI
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes$729,791
R01 · FY2022 · AI · contact PI
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes$783,184
R01 · FY2021 · AI · contact PI
NIH Support for Conferences and Scientific Meetings$7,500
R13 · FY2019 · AI · contact PI
Novel Reporter Phages to Detect Complex TB Drug Resistance and Persistence$385,037
R01 · FY2018 · AI · contact PI
Novel Reporter Phages to Detect Complex TB Drug Resistance and Persistence$248,711
R01 · FY2018 · AI · contact PI
Novel Reporter Phages to Detect Complex TB Drug Resistance and Persistence$633,748
R01 · FY2017 · AI · contact PI
Novel Reporter Phages to Detect Complex TB Drug Resistance and Persistence$650,498
R01 · FY2016 · AI · contact PI
Novel Reporter Phages to Detect Complex TB Drug Resistance and Persistence$420,693
R01 · FY2015 · AI · contact PI
Novel Reporter Phages to Detect Complex TB Drug Resistance and Persistence$210,346
R01 · FY2015 · AI · contact PI
Many Hosts of Mycobacteria Meeting VI$7,000
R13 · FY2015 · AI · contact PI
A Novel Oral Combination Pediatric HIV and TB Vaccine$501,915
R01 · FY2014 · DE
A Novel Oral Combination Pediatric HIV and TB Vaccine$502,986
R01 · FY2012 · DE
A Novel Oral Combination Pediatric HIV and TB Vaccine$518,663
R01 · FY2011 · DE
EFFICACY AND SAFETY OF LIVE ATTENUATED MYCOBACTERIUM TUBERCULOSIS VACCINES$37,186
P51 · FY2011 · RR · contact PI
Many Hosts of Mycobacteria Meeting$15,000
R13 · FY2011 · AI · contact PI
A Novel Oral Combination Pediatric HIV and TB Vaccine$545,865
R01 · FY2010 · DE
EFFICACY AND SAFETY OF LIVE ATTENUATED MYCOBACTERIUM TUBERCULOSIS VACCINES$61,801
P51 · FY2010 · RR · contact PI
A Novel Oral Combination Pediatric HIV and TB Vaccine$557,895
R01 · FY2009 · DE
A Novel Oral Combination Pediatric HIV and TB Vaccine$29,585
R01 · FY2009 · DE
Many Hosts of Mycobacteria Meeting$18,760
R13 · FY2009 · AI · contact PI
A Novel Oral Combination Pediatric HIV and TB Vaccine$687,840
R01 · FY2008 · DE
EFFICACY AND SAFETY OF LIVE ATTENUATED MYCOBACTERIUM TUBERCULOSIS VACCINES$23,596
P51 · FY2008 · RR · contact PI